Literature DB >> 23738630

Whole-mount evaluation of penectomies for penile cancer: feasibility, cost and comparison to routine sectioning.

Joshua J Ebel1, Ahmad Shabsigh, David S Sharp, Debra L Zynger.   

Abstract

AIMS: Pathological staging in penectomies may be difficult due to the anatomical complexity of penile anatomy, and may be additionally challenging due to the low volume at most institutions. Our study aimed to assess the feasibility of whole-mount processing for penectomy specimens. METHODS AND
RESULTS: A 7-year retrospective search for partial or radical penectomies identified 55 specimens, which were processed routinely (n = 31) from 2006 to 2009 and whole-mounted (n = 24) from 2010 to 2012. Routine cases used more slides per case compared to whole mounts (mean 10.4 versus 7.2). Recuts occurred more often in routine cases (12.9% versus 0%). More routine cases had additional blocks grossed (19.4% versus 4.2%). Upon review, five discrepancies that impacted pT staging were identified in the routine group, with none in the whole-mount group. The average estimated additional cost for each whole-mount case compared to routine processing was $40.74, with an increased turnaround time of 1 day.
CONCLUSIONS: Whole-mounting is a feasible technique for penectomy that can be utilized with minimal increased cost and turnaround time, and may improve staging. Institutions in which whole-mounting is already established for other organs, such as prostate, may wish to consider utilizing this format for penectomy specimens.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23738630     DOI: 10.1111/his.12149

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  1 in total

1.  Characteristic of Perineural Invasion in Hilar Cholangiocarcinoma Based on Whole-Mount Histologic Large Sections of Liver.

Authors:  Si-Yuan Wang; Nan Jiang; Jian-Ping Zeng; Shao-Qing Yu; Ying Xiao; Shuo Jin
Journal:  Front Oncol       Date:  2022-03-08       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.